Literature DB >> 15750155

Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.

Thomas Beyer1, Gerald Antoch, Andreas Bockisch, Joerg Stattaus.   

Abstract

UNLABELLED: Standard application of CT intravenous contrast agents in combined PET/CT may lead to high-density artifacts on CT and attenuation-corrected PET. To avoid associated diagnostic pitfalls, we designed and compared different intravenous contrast injection protocols for routine whole-body PET/CT.
METHODS: Whole-body PET/CT included a topogram and a single spiral CT scan (2-row) with or without intravenous contrast, followed by an emission scan. The CT scan was used for attenuation correction of the emission data. Four groups of 10 whole-body PET/CT referrals each were investigated: (A) no intravenous contrast agent, (B) biphasic injection (90 and 50 mL at 3 and 1.5 mL/s, respectively) of intravenous contrast (300 mg/mL iodine) and CT in the craniocaudal direction with a 30-s delay, (C) triple-phase injection (90, 40, and 40 mL at 3, 2, and 1.5 mL/s, respectively) in the craniocaudal direction with a 50-s delay, and (D) dual-phase injection (80 and 60 mL at 3 and 1.5 mL/s, respectively) in the caudocranial direction with a 50-s delay. CT image quality was assessed on a scale from 1 to 3, and CT and attenuation-corrected PET images were reviewed separately for contrast-induced artifacts.
RESULTS: Average CT image quality was poorest for protocol A (1.0) but improved to 2.8 when using intravenous contrast agents (protocols B-D). Only protocols B and C resulted in contrast-induced image artifacts that were limited to the thorax. The most homogeneous intravenous contrast enhancement without high-density image artifacts on either CT or PET after CT-based attenuation correction was achieved with protocol D.
CONCLUSION: Dual-phase intravenous contrast injection and CT in the caudocranial direction with a 50-s delay yields reproducible high image quality and is now used routinely for combined diagnostic PET/CT at our hospital.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750155

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging.

Authors:  Philip Aschoff; Christian Plathow; Thomas Beyer; Matthias P Lichy; Gunter Erb; Mehmet Ö Öksüz; Claus D Claussen; Christina Pfannenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-29       Impact factor: 9.236

2.  Calcified Lymph Nodes Causing Clinically Relevant Attenuation Correction Artifacts on PET/CT Imaging.

Authors:  Amar Mehta; Ajeet Mehta; Charles Laymon; Todd M Blodgett
Journal:  J Radiol Case Rep       Date:  2010-02-01

3.  Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT.

Authors:  Suzanne L Aquino; Landon B Kuester; Victorine V Muse; Elkan F Halpern; Alan J Fischman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-03       Impact factor: 9.236

4.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

Review 5.  False-positive FDG PET uptake--the role of PET/CT.

Authors:  Sandra J Rosenbaum; Thomas Lind; Gerald Antoch; Andreas Bockisch
Journal:  Eur Radiol       Date:  2005-12-17       Impact factor: 5.315

6.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.

Authors:  Anna C Pfannenberg; Philip Aschoff; Klaus Brechtel; Mark Müller; Roland Bares; Frank Paulsen; Jutta Scheiderbauer; Godehard Friedel; Claus D Claussen; Susanne M Eschmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-01       Impact factor: 9.236

7.  PET/CT artifacts.

Authors:  Todd M Blodgett; Ajeet S Mehta; Amar S Mehta; Charles M Laymon; Jonathan Carney; David W Townsend
Journal:  Clin Imaging       Date:  2011 Jan-Feb       Impact factor: 1.605

8.  Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer.

Authors:  M Bellomi; S Rizzo; L L Travaini; L Bazzi; G Trifirò; M G Zampino; D Radice; G Paganelli
Journal:  Radiol Med       Date:  2007-07-26       Impact factor: 3.469

9.  Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?

Authors:  Pierre Vera; Matthieu John Ouvrier; Sébastien Hapdey; Marc Thillays; Anne Sophie Pesquet; Brigitte Diologent; Françoise Callonec; Anne Hitzel; Agathe Edet-Sanson; Jean François Ménard; Fabrice Jardin; Hervé Tilly
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-11       Impact factor: 9.236

Review 10.  PET/CT imaging: what radiologists need to know.

Authors:  M Benamor; L Ollivier; H Brisse; G Moulin-Romsee; V Servois; S Neuenschwander
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.